[{"id":"4cd56a5a-7e2e-4298-bbc4-30c1187eaf1b","acronym":"ModiFY","url":"https://clinicaltrials.gov/study/NCT05329532","created_at":"2022-04-15T12:53:41.363Z","updated_at":"2024-07-02T16:36:00.168Z","phase":"Phase 1/2","brief_title":"Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer","source_id_and_acronym":"NCT05329532 - ModiFY","lead_sponsor":"Scancell Ltd","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Modi-1"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 04/04/2026","primary_completion_date":" 04/04/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2022-11-21"}]